BACKGROUND: The synthetic vasoactive intestinal peptide (VIP) analogue Ro 25-1553 is a selective VIP-PACAP type 2 (VPAC(2)) receptor agonist that causes a bronchodilatory effect in guinea pigs in vivo. The effect of Ro 25-1553 given by inhalation to patients with asthma was studied and compared with that of a long acting beta(2) adrenoceptor agonist. METHODS:Twenty four patients with moderate stable asthma participated in a double blind, randomised, placebo controlled, crossover study. The primary variable was bronchodilatory effect (increase in forced expiratory volume in 1 second, FEV(1)) after inhalation of Ro 25-1553 (100 microg or 600 microg) and formoterol (4.5 microg), respectively. Putative side effects were characterised by monitoring sitting blood pressure, serum potassium, electrocardiography and echocardiography. RESULTS: Inhalation of 600 microg Ro 25-1553 caused a rapid bronchodilatory effect (geometric mean increase in FEV(1) compared with placebo) within 3 minutes of 6% (95% CI 4 to 9), as did inhalation of formoterol (8% (95% CI 5 to 10)). The corresponding maximum bronchodilatory effect during 24 hours was similar for 600 microg Ro 25-1553 (7% (95% CI 4 to 10)) and the reference bronchodilator formoterol (10% (95% CI 7 to 12)). However, for both doses of Ro 25-1553 the bronchodilatory effect was attenuated 5 hours after inhalation whereas formoterol still had a bronchodilatory effect 12 hours after inhalation. Neither Ro 25-1553 nor formoterol produced any clinically relevant side effects. No drug related difference in adverse events was observed. CONCLUSION: Inhalation of a synthetic selective VPAC(2) receptor agonist constitutes a promising approach for bronchodilation in patients with asthma.
RCT Entities:
BACKGROUND: The synthetic vasoactive intestinal peptide (VIP) analogue Ro 25-1553 is a selective VIP-PACAP type 2 (VPAC(2)) receptor agonist that causes a bronchodilatory effect in guinea pigs in vivo. The effect of Ro 25-1553 given by inhalation to patients with asthma was studied and compared with that of a long acting beta(2) adrenoceptor agonist. METHODS: Twenty four patients with moderate stable asthma participated in a double blind, randomised, placebo controlled, crossover study. The primary variable was bronchodilatory effect (increase in forced expiratory volume in 1 second, FEV(1)) after inhalation of Ro 25-1553 (100 microg or 600 microg) and formoterol (4.5 microg), respectively. Putative side effects were characterised by monitoring sitting blood pressure, serum potassium, electrocardiography and echocardiography. RESULTS: Inhalation of 600 microg Ro 25-1553 caused a rapid bronchodilatory effect (geometric mean increase in FEV(1) compared with placebo) within 3 minutes of 6% (95% CI 4 to 9), as did inhalation of formoterol (8% (95% CI 5 to 10)). The corresponding maximum bronchodilatory effect during 24 hours was similar for 600 microg Ro 25-1553 (7% (95% CI 4 to 10)) and the reference bronchodilator formoterol (10% (95% CI 7 to 12)). However, for both doses of Ro 25-1553 the bronchodilatory effect was attenuated 5 hours after inhalation whereas formoterol still had a bronchodilatory effect 12 hours after inhalation. Neither Ro 25-1553 nor formoterol produced any clinically relevant side effects. No drug related difference in adverse events was observed. CONCLUSION: Inhalation of a synthetic selective VPAC(2) receptor agonist constitutes a promising approach for bronchodilation in patients with asthma.
Authors: M O'Donnell; R J Garippa; N Rinaldi; W M Selig; B Simko; L Renzetti; S A Tannu; M A Wasserman; A Welton; D R Bolin Journal: J Pharmacol Exp Ther Date: 1994-09 Impact factor: 4.030
Authors: M O'Donnell; R J Garippa; N Rinaldi; W M Selig; J E Tocker; S A Tannu; M A Wasserman; A Welton; D R Bolin Journal: J Pharmacol Exp Ther Date: 1994-09 Impact factor: 4.030
Authors: H D Lauenstein; D Quarcoo; L Plappert; C Schleh; M Nassimi; C Pilzner; S Rochlitzer; P Brabet; T Welte; H G Hoymann; N Krug; M Müller; E A Lerner; A Braun; D A Groneberg Journal: Clin Exp Allergy Date: 2010-11-09 Impact factor: 5.018
Authors: S A Tannu; L M Renzetti; N Tare; J D Ventre; D Lavelle; T A Lin; A Morschauser; J Paciorek; D R Bolin; H Michel; L Singer; M Hargaden; Id Knowles; P Gardiner; M Cazzola; L Calzetta; M G Matera; A Hicks Journal: Br J Pharmacol Date: 2010-11 Impact factor: 8.739
Authors: Sébastien Talbot; Raja-Elie E Abdulnour; Patrick R Burkett; Seungkyu Lee; Shane J F Cronin; Maud A Pascal; Cedric Laedermann; Simmie L Foster; Johnathan V Tran; Nicole Lai; Isaac M Chiu; Nader Ghasemlou; Matthew DiBiase; David Roberson; Christian Von Hehn; Busranour Agac; Oliver Haworth; Hiroyuki Seki; Josef M Penninger; Vijay K Kuchroo; Bruce P Bean; Bruce D Levy; Clifford J Woolf Journal: Neuron Date: 2015-06-25 Impact factor: 17.173
Authors: Gandhi F Pavón-Romero; Nancy Haydée Serrano-Pérez; Lizbeth García-Sánchez; Fernando Ramírez-Jiménez; Luis M Terán Journal: Front Cell Dev Biol Date: 2021-05-13
Authors: Rachel A Ross; Susanne S Hoeppner; Samantha N Hellberg; Emily B O'Day; Peter L Rosencrans; Kerry J Ressler; Víctor May; Naomi M Simon Journal: Neuropsychopharmacology Date: 2020-01-07 Impact factor: 8.294
Authors: Jun Yin; Liming Wang; Ning Yin; Arata Tabuchi; Hermann Kuppe; Gerhard Wolff; Wolfgang M Kuebler Journal: PLoS One Date: 2013-09-19 Impact factor: 3.240